Bringing together 400+ leading experts from the top industry and academic institutions, Oxford Global's Immuno UK 2024, featuring the 9th Annual Advances In Immuno-Oncology and 2nd Annual Targets and Cell Types In Immuno-Oncology Congresses, stands as the foremost venue to explore cutting-edge advancements in drug development strategies and innovative technologies.

Key Speakers Include

ELENI CHANTZOURA, Director of Discovery, MiNK Therapeutics

JONATHAN KWOK, Chief Executive Officer, Infinitopes

LIVIJA DEBAN, Chief Scientific Officer, Prokarium

MARTIN MILLER, Senior Director, Computational Biology, Oncology R&D, AstraZeneca

SARI PESONEN, Chief Scientific Officer, Valo Therapeutics

Book Now

WELCOME TO
Immuno 2024

On behalf of the entire Oxford Global team, I am delighted to welcome you to Immuno 2024. From new and exciting innovations to the latest in products and services, our event will bring together leading companies for engaging discussions, knowledge sharing and focused networking.

The Oxford Global team look forward to meeting you over the course of the event and will be on hand to ensure your time is both productive and enjoyable.

Oxford Global Marketing Ltd. has been producing cutting edge congresses and summits for the Life Sciences Industry for over 16 years. I am pleased to let you know that we have now successfully completed a transition from an in-person event organiser to one stop shop platform for all research-critical information pertaining to the Immuno space. We would like to invite you to visit our Immuno Content Portal to find out more about our brand-new membership offering, giving you access to the latest technology insights and research community we have been building over the last 16 years. You can register for the newsletter to get updates on upcoming activities within this series, stay up to date with industry news and more.

The event is designed to provide a comprehensive look at the current trends, challenges and developments impacting the sector. For a detailed breakdown of the areas we will discuss, please see the Session Topic Areas page, and use the Full Programme Agenda to identify which of our expert presentations are of the highest interest to you.

We want to create an environment where attendees can converse in smaller groups, so the programme will host a series of engaging discussions such as panels and workshops to encourage as much knowledge-sharing as possible.

We are hugely thankful to our speakers, who have given their time to provide interesting, thought-provoking presentations, and to our sponsoring companies, who have worked closely with us to provide you with unique opportunities to access the latest information on solutions and services that can directly impact and improve your research and results. Without their support this event would not be possible, so please do take some time to visit their stands in-person and featured sponsor pages on the event app (Swapcard). Once again, welcome to the event — we hope it will prove to be both educational and enjoyable for you.

Peter Franko

Senior Director, Business Development,
Oxford Global

Book Now

Linked in

✕ @OGConferences

Network and Knowledge-Share

400+ VPs, Directors & Senior Managers will be on-site, coming from leading healthcare, biotech, pharma and research institutions in the following fields and more:

- Immuno-Oncology
- Immunotherapy
- Translational Medicine
- Combination Therapies
- Clinical Development
- Target Validation
- Target Identification
- Cell Therapy
- Preclinical Development
- Molecular Pharmacology

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1-2-1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated refreshment (networking) breaks covering:

- Translational Tools
- Checkpoint Marker Detection
- Immune Cell Characterisation
- Tumour Models
- Computer-Aided Target Validation & Identification
- Functional Genomics
- Target Profiling
- Target Deconvolution
- Screening Technologies
- Druggability Assessment

Previous Attendee Profile

(Stats from Immuno 2023)

FUNCTION
54% – Scientist
20% – Director
19% – C - Level
7% - Manager/Senior

GEOGRAPHY
67% – UK
25% – Europe
8% – US

SECTOR
86% – Industry
10% – Academic
4% - Healthcare

Attended by these companies & many more:

AstraZeneca   abbvie   Bristol Myers Squibb   Genentech (A Member of the Roche Group)   Merck   Roche

SANOFI   Adaptimmune (TRANSFORMING T CELL THERAPY)   byondis   Crescendo biologics   Prokarium

Book Now

Linked in

X @OGConferences

Drive Innovation & Accelerate Research

Gold Sponsors

charles river

CROWN BIOSCIENCE

GenScript
Make Research Easy

Silver Sponsors

canopy
BIOSCIENCES A BRUKER COMPANY

GemPharmatech

JANVIER GROUP
BIOSCIENCES

Navinci

STANDARD
BIOTOOLS

scailyte

Thermo Fisher
SCIENTIFIC

Bronze Sponsors

BATAVIA
biosciences

BIOGNOSYS
NEXT GENERATION PROTEOMICS

Cell Signaling
TECHNOLOGY

Lunaphore
a biotechne brand

ImmunXperts
a Q² Solutions Company

Network & Programme Sponsors

Antibody Analytics

Concept Life Sciences
a Malvern Panalytical brand

CellCarta

ERBC
Connect non-clinical solutions, early.

HAWK
Biosystems

Histologix

nanion

novigenix

Personalis

proteome
sciences

RSSL

SGS

Volition

Book Now

Linked in

@OGConferences

Explore Curated & Insightful Content

Immuno 2024 features **2 days** of in-person cutting-edge presentations and knowledge-sharing, including **over 100** industry insights, sponsored presentations & think tank roundtable discussions.

Day One | 25 April 2024

Track 1: Discovery & Development: Cell & Gene and Combination Therapies

- Cell-based therapeutics: CAR T, CAR-NK cell therapies
- Future challenges with the development of advanced therapies for IO
- Personalised cell therapy & cancer neoepitopes
- Advanced immune regulation strategies
- Advancing gene therapies to target immune system responses

Track 2: Biomarkers, Precision Medicine & Multi-Omics In Immuno-Oncology

Part 1 – Biomarkers & Precision Medicine IO

- Biomarker strategies in the era of PD-1 checkpoint combination therapies
- Development & delivery of personalised immunotherapy
- New biomarker technologies in the prediction of response
- Technologies for biomarker development of patient populations
- Patient selection & stratification for immuno-oncology

Part 2 - Multi-Omics Guided Immuno-Oncology

- Utilisation of spatial technologies in immuno-oncology
- Genetic analysis technologies for immuno-oncology research
  » NextGen Sequencing
  » Microarrays

Track 3: IO Clinical Trials: Design, Data-Management & Case Studies

Part 1: Clinical Trial Design & Data Management

- Implementation of successful trial design strategies & new trends in trial design
- Patient-specific immunotherapy using adaptive clinical study designs
- Leveraging digital technologies & AI/ML in IO therapy development
- Using & managing IO datasets

Part 2: Clinical Development Case Studies

- Case Studies of IO Therapeutics in Clinical Stages:
  » Multi-Specific Immunotherapies
  » Checkpoint Inhibitors
  » Cell Therapies
- Protein aggregations and preventions

Track 4: Discovery of Novel Targets in Immuno-Oncology: Identification, Validation and Exploration

- Emerging target identification and validation strategies, methods
- Technological approaches:
  » High-throughput screening
  » Computational biology
  » Genomic sequencing
  » CRISPR
- Novel identification strategies
- Checkpoint inhibitors

Part 2: Myeloid and Stem Cells to Enhance the Development of Novel Therapeutics

- Case studies & latest developments in cellular therapies:
  » NK cells
  » Myeloid Cell
  » Stem cells – MSCs, HSCs, PSCs/iPSCs
- Solid tumours/Tumour microvironment

Day Two | 26 April 2024

Track 1: Discovery & Development: Intratumoral/Targeted Immunotherapies & Antibody Therapies

- Discovery & development of best-in-class therapeutic antibodies in IO
- Immunomodulatory therapeutic antibodies for cancer
- Bispecific antibody case studies
- Oncolytic virus platforms to refocus immune response from virus to tumour
- Immune redirection approaches in haematological malignancies and solid tumours

Track 2: Large & Small Molecule-Based Preclinical & Translational Development

Part 1 – Cancer Vaccines

- Cancer vaccine designs
- Safety and efficacy of cancer vaccines

Part 2 - Small and Large Molecule Based Development

- Case studies in checkpoint inhibitor discovery and combinations
- Immune modulation with large and small molecules
- New approaches for small molecule IO targets
- Preclinical models, including humanised & 3D mouse models
- Preclinical safety and efficacy and assay development
- Translational imaging and screening methods
- Novel predictive in vitro models using patient derived samples

Book Now

Linked in

X @OGConferences

Connect with Industry Influencers

Attracting leading experts & the brightest minds in the industry to educate, inform and inspire our attendees.

The following are confirmed Key Speakers for Immuno 2024.

MARTIN MILLER, Senior Director, AstraZeneca
Day One
08:50 — Multimodal Real World Data Reveals Immunogenomic Drivers Of Acquired And Primary Resistance To Immune Checkpoint Blockade

SYLWIA MARSHALL, Senior Director, Translational Sciences, InvoX Pharma
Day One
08:50 — Optimising And Selecting Doses In Clinical Trials

CHRISTINE ROTHE, Chief Development Officer, iOmx Therapeutics
Day Two
09:00 — Developing Potent Cancer Immunotherapies By Leveraging A Function-Based Target Discovery Platform

JONATHAN KWOK, Chief Executive Officer, Infinitopes
Day Two
09:00 — Peptide-Based Cancer Vaccines Directed Against The Tumour Microenvironment

Programme Highlights

Interactive Sessions

✓ Panel Discussion: Cancer Vaccines As Immuno Therapeutics

✓ Workshop: Multi-Omics Guided Immunotherapy Research

✓ Workshop: Preclinical & Clinical Development Case Studies

Key Presentations

✓ T Cell Redirection With Bispecific Antibodies: Strategies And Clinical Examples

✓ CD25 Targeting Eliminates Regulatory T cells And CD25+ blasts In Acute Myeloid Leukaemia

✓ Mechanism Of Actions Through Mass Spectrometry-Based Proteomics

✓ Contribution Of Component And Dose Selection And Challenges Of Combination Development

Book Now

Linked**in**
X @OGConferences

Gain Expertise from Thought Leaders

DAY ONE

MIGUEL GASPAR
Director, AstraZeneca

SARI PESONEN
Chief Scientific Officer, Valo Therapeutics

MARTIN MILLER
Senior Director, AstraZeneca

SYLWIA MARSHALL
Senior Director, Translational Sciences, InvoX Pharma

ALEXANDRA SEVKO
Director, Translational Research, Prokarium

PEDRO CORREA DE SAMPAIO
Chief Executive Officer, Neobe

RAHUL ROYCHOUDHURI
Professor, University of Cambridge

XI ZHAO
Head, Computational Oncology, Research and Development; Senior Principal Scientist, AbbVie; Genomics Research Center

KIERAN WHELTON
Data Scientist, Data Science & Analytics, AbbVie

ELENI CHANTZOURA
Director of Discovery, MiNK Therapeutics

MINI BHARATHAN
Senior Vice President, R&D & Translational Medicine, Arovella Therapeutics

MARIA LAURA GARCÍA BERMEJO
Scientific Director, Ramon & Cajal Health Research Institute

CANDICE JAMOIS
Senior Principal Clinical Pharmacology Leader, Roche

YONG-JIE LU
Professor in Molecular Oncology, Queen Mary University of London

FÁBIO ROSA
Co-Founder & Head of Research, Asgard Therapeutics

JOHAN PIJNENBORG
Chief Executive Officer, GlycoTherapeutics B.V.

JOHN BRIDGEMAN
Director of Cell Therapy Research, Instil Bio

ROBYN BROAD
Principal Scientist, Tumour Profiling, Translational Sciences, Adaptimmune

JENS KRINGELUM
Vice President, AI & Innovation, Evaxion Biotech

ANGELICA LOSKOG
Chief Executive Officer, Lokon Pharma AB

CYNTHIA CHAUVIN-FLEURENCE
Associate Principal Scientist, AstraZeneca

EMIKO DESVAUX
Principal Scientist, Translational Medicine, Sanofi

PHILLIP BRAILEY
Senior Scientist II, Crescendo Biologics

ØYSTEIN REKDAL
Chief Executive Officer, Lytix Biopharma

WILLIAM JACKSON
Senior Scientist, Bioarchitech Ltd

STEPHEN THORNE
Chief Scientific Officer, KaliVir Immunotherapeutics

SARAH-KIM FRIEDRICH-BECKER
Senior Principal Scientist, Abalos Therapeutics

MANI MUDALIAR
Target Analyst Director, Exscientia

MASSIMILIANO MELLONE
Senior Scientist, AstraZeneca

ILARIA MALANCHI
Group Leader, Francis Crick Institute

For more information on our speakers,
please read the biographies available on our **event app**

Book Now

Linked**in**

✕ @OGConferences

Gain Expertise from Thought Leaders

DAY TWO

LIVIJA DEBAN
Chief Scientific Officer, Prokarium

RAY JUPP
Chief Scientific Officer, Mestag Therapeutics

TIMO VAN DEN BERG
Senior Director, Immuno-oncology, Byondis

RAJ MEHTA
Founder, Chief Executive Officer & Director, Adendra Therapeutics

ALASTAIR CORBIN
Senior Scientist, Pathios Therapeutics

SOPHIA KARAGIANNIS
Professor of Translational Cancer Immunology and Immunotherapy, King's College London

BENOIT VAN DEN EYNDE
Professor, Ludwig Institute for Cancer Research, Oxford University / VOLT

RUSSELL LAMONTAGN
Chief Executive Officer, Boston Immune Technologies and Therapeutics, Inc.

JOHN MAHER
Chief Scientific Officer, Leucid Bio

RICK KAMPS
Head Research Engineer in the Department of Toxicogenomics, Maastricht University

LAURÈNE POUSSE
Scientist & Research Project Leader, Roche

CHRISTINE ROTHE
Chief Development Officer, iOmx Therapeutics

JON MOORE
Chief Scientific Officer and Co-Founder, Epitopea

SIMON BARRY
Executive Director, AstraZeneca

KLAUS OKKENHAUG
Professor of Immunology, University of Cambridge

PIERRE DÖNNES
Co-Founder, Strike Pharma AB

YI-RU YU
Senior Scientist, Pilatus Biosciences

MARIA STELLA SASSO
Senior Principal Scientist, Akamis Bio Ltd

THORSTEN ROSS
Vice President, Preclinical Research & Translation Strategy, CatalYm

MARIA PIHLGREN BOSCH
Senior Director and Project Team Leader, IGI

PHILIP ARLEN
Chief Executive Officer, Precision Biologics

KENNETH CROOK
Head of Translational Medicine, Engimmune Therapeutics

IDA UDDBÄCK
Senior Scientist, Alligator Bioscience

NATALIA VENETZ
Senior Scientist, Oncology Research, Molecular Partners

PHILIP BEER
Chief Scientific Officer, Step Pharma

ERIC O'NEILL
Professor of Cell and Molecular Biology, University of Oxford

CHRIS HOLLAND
Senior Manager, Research, Experimental Immunology, Immunocore

JONATHAN KWOK
Chief Executive Officer, Infinitopes

MARK CRAGG
Professor of Experimental Cancer Research, University of Southampton

AMIT GROVER
Associate Principal Scientist, AstraZeneca

MARIA AMANN
Senior Principal Scientist, Roche

For more information on our speakers, please read the biographies available on our **event app**

Book Now

Linked**in**

✕ @OGConferences

DAY ONE

08:30   **Oxford Global Welcome Address** *(Taking place in each conference room)*

	TRACK 1: DISCOVERY & DEVELOPMENT: CELL & GENE AND COMBINATION THERAPIES	TRACK 2: BIOMARKERS, PRECISION MEDICINE & MULTI-OMICS IN IMMUNO-ONCOLOGY	TRACK 3: IO CLINICAL TRIALS: DESIGN, DATA-MANAGEMENT & CASE STUDIES	TRACK 4, PART 1: DISCOVERY OF NOVEL TARGETS IN IMMUNO-ONCOLOGY: IDENTIFICATION, VALIDATION AND EXPLORATION
	Track Chair: DEEPAK BHERE, Assistant Professor and Principal Investigator, **University of South Carolina**	**Track Chair:** FABIEN DELAHAYE, Senior Principal Scientist, **Sanofi**	**Track Chair:** ANGELICA LOSKOG, Chief Executive Officer, **Lokon Pharma AB**	**Track Chair:** ANGÉLIQUE BIANCOTTO, Cellular Proteomic Group Head, **Sanofi**
08:50	**Track Keynote Address: T Cell Redirection With Bispecific Antibodies: Strategies And Clinical Examples** • T cell redirection therapies such as T cell engagers are clinically validated therapeutic approaches to cancer • However toxicity remains a big issue in these therapies that can impact overall efficacy, particularly in solid tumours • Multiple engineering and clinical development strategies are currently being pursued to improve the therapeutic index of T cell redirection therapies MIGUEL GASPAR, Director, **AstraZeneca**	**Track Keynote Address: Biomarkers & Therapeutic Targets** • Importance of the identification and validation of precise biomarkers for metastatic renal carcinoma patient stratification in order to select appropriate treatment • Relevance of unveiling mechanisms responsible for immunotherapy resistance • Future perspectives: overcoming immunotherapy resistance by combining immunotherapy with radiotherapy • Biomarkers for selecting patients that can benefit from combination treatments MARIA LAURA GARCÍA BERMEJO, Scientific Director, **Ramon & Cajal Health Research Institute**	**Track Keynote Address: Optimising And Selecting Doses In Clinical Trials** • Clinical dose selection/ optimisation is undergoing a paradigm shift due to initiatives such as FDA's Project Optimus. Deep understanding of pharmacology and biomarker data can significantly enhance the dose selection decision making process. An overview of strategy for dose selection for agonists will be discussed in the context of invoX Pharma's CD137 bispecific agonists currently being explored in Phase 1 studies in solid tumours SYLWIA MARSHALL, Senior Director, Translational Sciences, **InvoX Pharma**	**Track Keynote Address:** AI-Based Target Discovery And Prioritisation • Selecting the right target is the first step in creating success in drug discovery and development. Each target selection is a significant decision that impacts on the future success of the pipeline, and success in the clinic will depend on that initial decision. With the advancement in Machine Learning methods and Large Language Models, it has become possible to automate and prioritize gene-disease associations from multiple data sources, including scientific publications. Here, I will discuss various AI-based approaches, including language models and graph-based methods used in target identification and prioritization MANI MUDALIAR, Target Analyst Director, **Exscientia**
09:10	**End To End CAR Optimization & Development: For Faster Entrance Into The Clinic** • While cell therapies are emerging, their biological difference to other modalities imply an adaption in the development pipeline from design to IND-filing. A HER2-targeting CAR-T cell therapy has been generated as a model system to demonstrate requirements in the cell therapy preclinical testing STEPHEN HOLLAND, Head of Project Management, **Charles River** *charles river*	**Spatial Interrogation Of The Tumor Microenvironment: CellScape™ And Spatial Subcellular Insights** • Join us for a presentation where Rachid El Morabiti introduces CellScape™, a groundbreaking image-based platform revolutionizing tumor microenvironment proteomics. Discover how CellScape™ facilitates high-plex quantitative, single-cell spatial proteomics, enabling researchers to explore complex tissue microenvironments with unprecedented precision RACHID EL MORABITI, Business Development Manager, **Canopy Biosciences** *canopy BIOSCIENCES A BRUKER COMPANY*	*Delegates welcome to attend co-located sessions*	*Delegates welcome to attend co-located sessions*
09:30	**Enhancing Drug Discovery Success With Preclinical Solutions** ADRIEN MOSSU, Senior Manager of Scientific Engagement, **Crown Bioscience** *CROWN BIOSCIENCE*	**Illuminating Function In Spatial Biology With In Situ Interactomics To Better Explore Immune Markers In The TME** • Learn how proximity-based technology enables development of precise biomarkers and their application across protein research stages, from discovery to clinical use • Discover how in situ proximity ligation technology goes beyond immunohistochemistry and can work in conjunction with spatial multiplexing techniques to illuminate protein function at the immune cell and tumor interface • Explore the potential of automated in situ proximity-based protein detection in pre-clinical and clinical research, focusing on immune checkpoints like PDL1-PD1 and other immune cell interaction markers SUBHAM BASU, Chief Business Officer, **Navinci Diagnostics** *Navinci*	*Delegates welcome to attend co-located sessions*	**Accelerating Antibody Discovery For Difficult Targets Through mRNA Immunization And Beacon Single Cell Technology** • Despite demonstrated efficiency in antibody generation, classical immunization strategies and subsequent hybridoma generation often face strong limitations when it comes to speed and poorly immunogenic membrane proteins with short extracellular domains • Innovative approaches combining RNA immunization and single cell screening provide unique opportunities to dramatically speed up antibody discovery against such challenging targets FRANÇOIS ROMAGNÉ, Scientific Director, **MImAbs** *JANVIER GROUP BIOSCIENCES*

Book Now

Linked**in**

✖ @OGConferences

	TRACK 1: DISCOVERY & DEVELOPMENT: CELL & GENE AND COMBINATION THERAPIES	TRACK 2: BIOMARKERS, PRECISION MEDICINE & MULTI-OMICS IN IMMUNO-ONCOLOGY	TRACK 3: IO CLINICAL TRIALS: DESIGN, DATA-MANAGEMENT & CASE STUDIES	TRACK 4, PART 1: DISCOVERY OF NOVEL TARGETS IN IMMUNO-ONCOLOGY: IDENTIFICATION, VALIDATION AND EXPLORATION
09:50	**Therapeutic Drug Development For Malignant Brain Tumors** • Therapeutic development pipeline for stem cell products for advanced brain tumors • Development of combinatorial approaches to target glioblastoma DEEPAK BHERE, Assistant Professor and Principal Investigator, **University of South Carolina**	**Unraveling Tumor-Associated NK Cells: Bridging Patient Profiling To Translational Preclinical Model Development** • Comprehensive journey from patient-specific NK cell profiling to the development of translational preclinical models, aiming to decipher the intricacies of their involvement in cancer progression and treatment response. This presentation will address potential applications of NK cell-based therapies in advancing precision medicine in cancer EMIKO DESVAUX, Principal Scientist, Translational Medicine, **Sanofi**	**Challenges Of Using Predictive Analytics Techniques In Site Identification/Selection And The Known-Unknowns In Predicting Highest-Performing Sites** • Why use predictive analytics techniques to create site lists? • Data sources & features • Mapping & target variables • Challenges in data • Methodologies • Potential Solutions • Next generation KIERAN WHELTON, Data Scientist, Data Science & Analytics, **AbbVie**	**The Impact Of Cancer-Associated Fibroblasts Targeting On Immune-Checkpoint Blockade Resistance** • Patients with immuno-excluded tumours rich in myofibroblastic CAF are commonly resistant to immune checkpoint blockade (ICB) • Here, we identified Ataxia Telangiectasia mutated ATM as a central regulator of the myoCAF phenotype • Stromal ATM targeting suppresses myoCAF-rich tumour growth, promotes intra-tumoral CD8 T-cell infiltration, and potentiates response to ICB, potentially providing a new rationale for combination with ICB in CAF-rich tumours MASSIMILIANO MELLONE, Senior Scientist, **AstraZeneca**
10:10	**MORNING BREAK**	🤝 1-2-1 Meetings x4	🖼 Poster Displays	
11:30	**Integrating Single-Cell Transcriptomics With Artificial Intelligence Reveals Pan-Cancer Biomarkers Of Brain Metastasis** • We leveraged scRNA-seq data from six cancer types and combined with convolutional neural network (CNN)-based ScaiVision algorithm to identify a predictive pan-cancer brain metastasis signature from primary tumour biopsies FILIPA TEIXEIRA, Project & Business Development Manager, **Scailyte**	**Innovative CST® Solutions For Immuno-Oncology And Spatial Biology: CAR Linker Antibodies And SignalStar™ Multiplex IHC** Attend our CST talk; discover what you'll learn about: • Antibody validation: "Your assay is as good as your antibody is specific." • CAR-Linker Antibodies: Detecting CAR-constructs independent of the selected target • Custom conjugation: Our world class conjugation team got you covered! • SignalStar mIHC: Spatial Biology has a new Star! YANNICK NOSSIN, Field Application Scientist, **Cell Signaling Technology**	*Delegates welcome to attend co-located sessions*	**Growing Precision Cancer Therapies: A Novel Culture Medium For Patient-Derived Tumor Models And Applications In Immuno-Oncology** • Introducing OncoPro Tumoroid Culture Medium, which enables the culture of patient-derived tumor cells while preserving patient-specific mutations and gene expression. The use of OncoPro tumoroids in T and NK cell killing assays will be highlighted MATTHEW DALLAS, Senior Manager, Cell Biology R&D, **Thermofisher Scientific**
11:50	**Immune Regulation Strategies** • Cell therapy is revolutionising modern medicine. However, the limited persistence and functionality of transferred cells often hampers long-term efficacy. Employing novel gene modulation techniques to fine-tune the activity of transcription factors, we have been able to enhance both cell survival and function of adoptively transferred T cells in vivo, driving improved efficacy in preclinical cell therapy models. The findings may have therapeutic application in CAR T cell therapy, TIL therapy and other emerging cell therapy modalities RAHUL ROYCHOUDHURI, Professor, **University of Cambridge**	**Multimodal Real World Data Reveals Immunogenomic Drivers Of Acquired And Primary Resistance To Immune Checkpoint Blockade** • At AstraZeneca's Oncology Data Science, we aim to unlock the potential of computational and ML/AI approaches to address difficult questions such as why some cancer patients fail or have short lived response to immune checkpoint blockade (ICB) immunotherapy • We have analysed clinical endpoints together with >10.000 of DNA and RNA profiled samples in the Tempus real-world database to identify the immunogenomic drivers of acquired and primary resistance to ICB in lung, breast, bladder and head and neck cancers • Post-ICB, acquired resistant patients showed a significantly inflamed tumour microenvironment (TME) as well as selection for mutations in genes involved in known immune escape pathways • Our data science-based, multi-modal analysis of post therapy biopsies has given insights for patient selection strategies and provides rational into combination treatment options for acquired resistant patients MARTIN MILLER, Senior Director, **AstraZeneca**	**Presentation 1 (10min): Immunostimulatory Gene Therapy (CD40L/4-1BBL) To Inflame The Tumour Microenvironment – From Bench To Phase II** • Signalling via CD40 and 4-1BB triggers Th1 type of immune reactions and subsequent anti-tumour responses in cancer • LOAd703 encodes TMZ-CD40L and 4-1BBL and is under evaluation in several indications including pancreatic-, biliary-, ovarian-, colorectal cancer and melanoma. The presentation will show preclinical and clinical data • LOAd703 can be used as monotherapy or as combination treatments with chemotherapy or other immunotherapies such as checkpoint blockade antibodies ANGELICA LOSKOG, Chief Executive Officer, **Lokon Pharma AB** **Presentation 2 (10min): Enabling Cancer Immunotherapy Through Engineered Live Biotherapeutics** • The microenvironment of solid tumours creates barriers to immune cell infiltration impairing immunotherapy success • Synthetic biology enabled engineering of live biotherapeutics enables local tumour microenvironment remodeling • Preclinical data shows safe, localized and effective checkpoint inhibitor responses in refractory models PEDRO CORREA DE SAMPAIO, Chief Executive Officer, **Neobe**	**Reprogramming Macrophages With IgE Immunotherapy To Target Solid Tumours** • We have demonstrated that engineered anti-tumour IgE class antibodies can restrict cancer growth by immune effector mechanisms which are known to be employed by this antibody class against parasites. IgE immunotherapy potentiates recruitment and stimulation of macrophages within the tumour microenvironment. We will discuss the pre-clinical and clinical development of our first-in-class IgE and the mechanisms by which this antibody class can reconfigure the tumour microenvironment and activate previously-untapped immune mechanisms against tumours SOPHIA KARAGIANNIS, Professor of Translational Cancer Immunology and Immunotherapy, **King's College London**

Book Now

Linked in
✕ @OGConferences

TRACK 1: DISCOVERY & DEVELOPMENT: CELL & GENE AND COMBINATION THERAPIES	TRACK 2: BIOMARKERS, PRECISION MEDICINE & MULTI-OMICS IN IMMUNO-ONCOLOGY	TRACK 3: IO CLINICAL TRIALS: DESIGN, DATA-MANAGEMENT & CASE STUDIES	TRACK 4, PART 1: DISCOVERY OF NOVEL TARGETS IN IMMUNO-ONCOLOGY: IDENTIFICATION, VALIDATION AND EXPLORATION

12:10

Fully Automated Spatial Multiomics To Profile The Tumor Microenvironment

- Spatial RNA and protein profiling are required to discover and validate biomarkers
- Our fully-automated multiomics approach integrates RNAscope™ and sequential immunofluorescence (seqIF™) to co-detect RNA and proteins on the same section
- Examining cytokine's cellular source can provide essential insights into CAR-T target safety, biodistribution, and tumor infiltration

BRYAN SERRELS, Technical Sales Specialist; NATALIE ROWE, Account Manager, ACD, **Lunaphore, A Bio-Techne Brand**; **Advanced Cell Diagnostics, A Bio-Techne Brand**

Quantitative Profiling Of The HLA I Immunopeptidome In Drug Discovery

- Biognosys has developed a robust pipeline for HLA I/MHC Class I immunopeptidome profiling using tissue and cells
- This presentation will outline the workflow and several case studies where discovery and targeted immunopeptidome profiling were used in pre-clinical studies

DAN REDFERN, Senior Business Development Manager UK & Nordics, **Biognosys**

Scalable Process Development Of THEO-260 Oncolytic Adenovirus For Clinical Manufacturing

- Batavia Biosciences has successfully developed a scalable process for clinical manufacturing of oncolytic adenovirus THEO-260, targeting ovarian cancer, developed by Theolytics. The process was developed at 10L scale and was further scaled up to 40L scale, producing an Engineering batch for TOX study and an GMP batch for Phase 1 clinical trial

MANAS SAHOO, Senior Scientist DSP, **Batavia**

Delegates welcome to attend co-located sessions

12:30

Roundtable: Innovations In The Discovery And Development Of Novel Cellular Therapies

- CAR T-cell therapies
- NK cells
- iNKT cells
- TILs
- Gamma Deltas

Co-Moderators:
AMIT GROVER, Associate Principal Scientist, **AstraZeneca**

ENAS ABU-SHAH, Lecturer in Immunology, **University of Oxford**

Roundtable: Innovations In Biomarkers-Driven IO

- Detection & characterisation of biomarkers for IO
- Patient stratification & selection
- Latest developments & future outlook

Co-Moderators:
YONG-JIE LU, Professor in Molecular Oncology, **Queen Mary University of London**

MARIA LAURA GARCÍA BERMEJO, Scientific Director, **Ramon & Cajal Health Research Institute**

Panel Discussion: Advances In Oncolytic Virotherapies: Exploring The Latest Developments And Real-World Use Cases

- Engineering and optimization strategies
- Addressing safety and immune response challenges in clinical trial therapies
- Effective delivery of oncolytic viruses to solid tumours
- Augmenting therapeutic outcomes through combined virotherapy approaches

Moderator: ANGELICA LOSKOG, Chief Executive Officer, **Lokon Pharma AB**

Panellists:
WILLIAM JACKSON, Senior Scientist, **Bioarchitech Ltd**
STEPHEN THORNE, Chief Scientific Officer, **KaliVir Immunotherapeutics**

Panel Discussion: Identification, Validation & Exploration Of Novel Targets In Immuno-Oncology

- Emerging targets & validating emerging targets with 'traditional' approaches
- Challenges of target identification with novel technologies
- Immunomodulatory inhibitor and agonist targets, stromal and immune cell targets
- Strategies for rational combination immunotherapy

Moderator: NISIT KHANDELWAL, Founder and Former Chief Technology Officer, **iOmx Therapeutics**

Panellists:
MANI MUDALIAR, Target Analyst Director, **Exscientia**
ROB BOYD, Vice President R&D, **Elasmogen**
SUBHAM BASU, Chief Business Officer, **Navinci Diagnostics**

13:10

LUNCH BREAK	1-2-1 Meetings x3	Poster Displays

TRACK 1: DISCOVERY & DEVELOPMENT: CELL & GENE AND COMBINATION THERAPIES	TRACK 2: BIOMARKERS, PRECISION MEDICINE & MULTI-OMICS IN IMMUNO-ONCOLOGY	TRACK 3: IO CLINICAL TRIALS: DESIGN, DATA-MANAGEMENT & CASE STUDIES	TRACK 4, PART 2: MYELOID AND STEM CELLS TO ENHANCE THE DEVELOPMENT OF NOVEL THERAPEUTICS

Track Chair: DEEPAK BHERE, Assistant Professor and Principal Investigator, **University of South Carolina**

Track Chair: FABIEN DELAHAYE, Senior Principal Scientist, **Sanofi**

Track Chair: JENS KRINGELUM, Vice President, AI & Innovation, **Evaxion Biotech**

Track Chair: RICK KAMPS, Head Research Engineer in the Department of Toxicogenomics, **Maastricht University**

14:10

IndEx-2: An Advanced, Tailorable Cell Line Platform for Comprehensive In Vitro Evaluation of Safety And Efficacy of Antibody-Based Therapeutics And Immune Cell Therapies

- We introduce IndEx-2, a customisable cell line platform that enables precise, tuneable control of target antigen expression across a wide dynamic range and its employment in determining the impact of antigen expression on the safety and efficacy of antibody-based therapeutics and immune cell therapies. We determine activation thresholds in various scenarios including CAR-T therapies and T-cell engagers demonstrating the platform's effectiveness in selecting optimal therapeutic candidates and generating data of translational value

AGAPITOS PATAKAS, Chief Scientific Officer, **Antibody Analytics**

PD-1/PD-L1 Functional Engagement Quantified By QF-Pro® In NSCLC Is A Strong Predictor Of Immune Checkpoint Inhibitors Response

- Using HAWK's QF-Pro® technology to measure PD 1/PD L1 interaction in NSCLC tumour samples of a validation cohort of 188 patients, we very precisely predicted patients' response to immune checkpoint inhibitors treatment. These results beat the current gold standard biomarker PD-L1 TPS who failed to stratify these patients. QF-Pro® offers the most powerful tool to identify the subset of patients with high expression of PD-L1 TPS that are resistant to treatment and, more strikingly, also PD-L1 TPS <1% responders who, under current guidelines, would not have been considered for ICI therapies. In summary QF-Pro® prepares for superior patient stratification and direct integration into clinical practice

VERONIQUE CALLEJA, Chief Scientific Officer, **HAWK Biosystems**

High-Plex Whole Slide Spatial Biology Assays Powered By The Hyperion XTi

Introducing Hyperion XTi, a revolutionary Imaging Mass Cytometry System. 5x faster detection, unparalleled sensitivity for dim markers, walk-away flow cytometry, and new imaging modes. Ultra-fast whole slide imaging and intelligent ROI selection redefine high-throughput cytometry

HESTER KOPPEJAN, Field Application Specialist II - Cytometry and Tissue Imaging, **Standard BioTools Inc**

Delegates welcome to attend co-located sessions

Book Now

Linked in

X @OGConferences

TRACK 1: DISCOVERY & DEVELOPMENT: CELL & GENE AND COMBINATION THERAPIES	TRACK 2: BIOMARKERS, PRECISION MEDICINE & MULTI-OMICS IN IMMUNO-ONCOLOGY	TRACK 3: IO CLINICAL TRIALS: DESIGN, DATA-MANAGEMENT & CASE STUDIES	TRACK 4, PART 2: MYELOID AND STEM CELLS TO ENHANCE THE DEVELOPMENT OF NOVEL THERAPEUTICS

14:30

Track 1 — The CoStAR Platform, A Novel Engineering Strategy To Enhance Tumour Infiltrating Lymphocyte Activity

- Here, we describe a chimeric costimulatory antigen receptor (CoStAR) designed to boost TIL activity in the TME. CoStAR is shown to be intimately dependent on the provision of signal 1 delivered through the TCR, with concomitant CoStAR and TCR binding boosting T-cell and TIL activity above that seen with TCR alone. CoStAR is shown to enhance proliferation and cytokine secretion, enhance tumour control in several in vivo models, and enhance TIL activity across a range of tumour indications

JOHN BRIDGEMAN, Research Director, **Instil Bio**

Track 2 — Circulating Biomarkers In Immuno-Oncology

- Cancer immune therapy is the most important achievement in cancer treatment in recent decades, particularly immune checkpoint therapies. Current onco-immunological mechanism and response studies to improve immunotherapy efficacy, predominantly focus on cancer tissues, including cancer cell and the tumour microenvironment changes. Systemic immune response occurs during cancer development. My talk will focus on systemic immune response and circulating cancer biomarkers

YONG-JIE LU, Professor in Molecular Oncology, **Queen Mary University of London**

Track 3 — Workshop: Preclinical & Clinical Development Case Studies - Presentation 1: mRNA-4157 Individualized Neoantigen Therapy: mRNA Therapeutics Coming Of Age In Cancer

- mRNA as a therapeutic option in treating cancer
- The role of neoantigen therapy
- The early development of mRNA-4157 and a summary of the randomized ph2 results

ROBERT MEEHAN, Senior Director, Clinical Development, **Moderna**

Track 4 — Overcoming Immune Suppression Within The Tumour Microenvironment

- There is growing appreciation of the depth of interaction between tumour cells and their microenvironment which modulates tumour growth, proliferation and immune suppression. The impact of these interactions on antibody immunotherapy is poorly defined. This presentation will discuss several key interactions between the host and the tumour in different anatomical niches that impact different types of antibody immunotherapy and how they might be targeted to improve treatment efficacy

MARK CRAGG, Professor of Experimental Cancer Research, **University of Southampton**

14:50

Track 1 — Targeting Solid Tumours Through Cell Therapies

- Precise genome editing has revolutionized therapeutic approaches for various human disorders, including cancer. In the context of solid tumour and complex models, this tool has enabled the discovery and development of next-generation T cell-based immunotherapies with enhanced efficacy profile. These novel therapeutic approaches offer the potential to transform personalized treatments and deliver life-changing medicines

CYNTHIA CHAUVIN-FLEURENCE, Associate Principal Scientist, **AstraZeneca**

Track 2 — Workshop: Multi-Omics Guided Immunotherapy Research - Presentation 1: Harness Synergies Between Immunotherapy And Tumor Targeting Therapies: A Multi-Omics Driven Optimization Strategy For Combination

- Evidence for ADCs inducing immune responses supports combination potential with immune check point inhibitors
- Exploring the Synergies Between Immune Therapy and Tumor Antigen Directed Therapies in small cell lung cancer, through comprehensive characterization tumor microenvironment and in-silico identification of therapeutic vulnerabilities for the disease

XI ZHAO, Head, Computational Oncology, Research and Development; Senior Principal Scientist, **AbbVie; Genomics Research Center**

Track 3 — Presentation 2: Personalised Cancer Vaccines: Levering hERVs As Vaccine Targets To Overcome Limitations In Low-Mutational Burden Cancers

- Personalized cancer vaccines targeting tumor specific mutations have obtained PoC in humans
- Many cancer types are not suitable targets for traditional personalised cancer vaccines due to the low number of mutations
- Human endogenous retroviruses (hERVs) constitute a novel type of cancer vaccine target to treat cancers with a low mutational burden
- Evaxion has developed ObsERV to design personalized cancer vaccines based on hERVS - Preclinical PoC has been obtained

JENS KRINGELUM, Vice President, AI & Innovation, **Evaxion Biotech**

Track 4 — Panel Discussion: Exploring Different Cell Types In The Tumour Microenvironment

- Fibroblasts, macrophages, B cells, dendritic cells, T cells, myeloid cells
- New modality approaches
  » Checkpoint inhibitors
  » Immune adjuvant

Panellists:

SOPHIA KARAGIANNIS, Professor of Translational Cancer Immunology and Immunotherapy, **King's College London**

MARK CRAGG, Professor of Experimental Cancer Research, **University of Southampton**

ADRIEN MOSSU, Senior Manager of Scientific Engagement, **Crown Bioscience**

15:10 — AFTERNOON BREAK | 1-2-1 Meetings x3 | Poster Displays

---

16:10

Track 1 — Director-Level Panel Discussion: Advancing IO Partnerships 2024

- Novel therapeutic approaches & collaborations in therapeutics development
- Collaborations in clinical trials
- Successful partnership strategies in IO

Moderator: PHILIP ARLEN, Chief Executive Officer, **Precision Biologics**
Panellist:
RUSSELL LAMONTAGNE, Chief Executive Officer, **Boston Immune Technologies and Therapeutics, Inc.**

Track 2 — Workshop: Multi-Omics Guided Immunotherapy Research Contd. - Presentation 2: Characterising The Tumour Microenvironment In Solid Tumours Following Cell-Based Therapy Through Immunophenotyping And Spatial Biology

- Multiplex immunofluorescence (mIF) and spatial biology assays offer the advantage of preserving the architectural features of the tumour microenvironment (TME) and revealing the spatial relationships between tumour cells and immune cells that are present
- I will show examples of patient pre- and post-treatment biopsies for multiple indications to demonstrate how we use quantify cell densities of subsets of infiltrating immune cells, observe their spatial patterns within the tumours and begin to understand potential mechanisms of resistance

ROBYN BROAD, Principal Scientist, Tumour Profiling, Translational Sciences, **Adaptimmune**

Track 3 — Workshop: Preclinical & Clinical Development Case Studies Contd. - Presentation 3: Development Of Novel Multi-Specific Immunotherapies

- Pre-clinical pharmacology of CB307, Crescendo Biologics' PSMA x CD137 lead clinical asset
- Introduction to CB699, Crescendo Biologics' next generation tri-specific molecule

PHILLIP BRAILEY, Senior Scientist II, **Crescendo Biologics**

Track 4 — Translational Genomics In Oncology: An Overview Of Different Sequencing Strategies In Using Single-Cell Data Analysis

- The Area of Single-Cell Sequencing in Oncogenic Diseases
- Autologous Stem Cell Therapy
- Translational Medicine of Oncogenic Diseases

RICK KAMPS, Head Research Engineer in the Department of Toxicogenomics, **Maastricht University**

Book Now

Linked in

X @OGConferences

	TRACK 1:DISCOVERY & DEVELOPMENT: CELL & GENE AND COMBINATION THERAPIES	TRACK 2: BIOMARKERS, PRECISION MEDICINE & MULTI-OMICS IN IMMUNO-ONCOLOGY	TRACK 3: IO CLINICAL TRIALS: DESIGN, DATA-MANAGEMENT & CASE STUDIES	TRACK 4, PART 2: MYELOID AND STEM CELLS TO ENHANCE THE DEVELOPMENT OF NOVEL THERAPEUTICS
16:30	**Director-Level Panel Discussion Contd.:** Advancing IO Partnerships 2024 • Novel therapeutic approaches & collaborations in therapeutics development • Collaborations in clinical trials • Successful strategic partnership strategies in IO **Moderator:** PHILIP ARLEN, Chief Executive Officer, **Precision Biologics** **Panellist:** RUSSELL LAMONTAGNE, Chief Executive Officer, **Boston Immune Technologies and Therapeutics, Inc.**	**Panel Discussion:** Multi-Omics Guided Immunotherapy Research • Leveraging spatial technologies to uncover innovations in IO • Understanding the most exciting current applications in IO and how companies are turning theory into a practical reality • Outlining the main challenges that we need to overcome as an industry in 2024 • Laying data foundations for AI/ML applications • Computational approaches to analyse spatial data	**Panel Discussion:** Clinical Development Case Studies • What will be the next breakthrough clinical data • In cancer, for novel treatment regimes, we normally start in very difficult to treat populations and works our way up easier to treat cancers – is this the right approach or do we risk discontinuing good regimes due to no measurable efficacy in difficult settings • What indications to go for in early clinical trials • How do we meet investors/management expectations to phase-I clinical data	**Targeting Myeloid Cells In Solid Tumours** • Immunosuppressive effects of myeloid cells including MDSCs, and TAMs pose a major challenge to the resistance to standard-of-care (SOC) cancer immunotherapy. Therefore, targeting immune checkpoints on these myeloid cells alone or in combinations with other IO drugs could be a viable strategy to enhance the patient response to SOC immunotherapy • At AZ we are using a multipronged approach to identify druggable targets expressed on tumour associated myeloid cells AMIT GROVER, Associate Principal Scientist, **AstraZeneca**
16:50	**Role Of Emergency Granulopoiesis In Metastases** • Metastasis to the bone occur years after cancer resection, what drive metastatic reactivation is largely unknown • We present an extramedullary bone model to study dormancy reactivation • Emergency granulopoiesis can nudge dormant cells into a proliferative state and increased the chances of recurrence • HMGB2, can alone increase chances of metastasis ILARIA MALANCHI, Group Leader, **Francis Crick Institute**	**Panellists:** MARTIN MILLER, Senior Director, **AstraZeneca** ROBYN BROAD, Principal Scientist, Tumour Profiling, Translational Sciences, **Adaptimmune** XI ZHAO, Head, Computational Oncology, Research and Development; Senior Principal Scientist, **AbbVie; Genomics Research Center**	**Moderator:** JENS KRINGELUM, Vice President, AI & Innovation, **Evaxion Biotech** **Panellist:** ROBERT MEEHAN, Senior Director, Clinical Development, **Moderna**	**Roundtable Discussion 1: Overcoming Resistance To Immunotherapy Through Orthogonal Combinatorial Approaches** **Moderator:** LIVIJA DEBAN, Chief Scientific Officer, **Prokarium** **Roundtable Discussion 2: Response Biomarkers For IO Therapies: Not Enough Data Or Too Much?** **Moderator:** PHILIP BEER, Chief Scientific Officer, **Step Pharma** **Roundtable Discussion 3: Improving Clinical Outcomes Of Current I-O Therapies** **Moderator:** PHILIP ARLEN, Chief Executive Officer, **Precision Biologics**
17:10	**End of Day 1** **Drinks & Speed Networking**			

Book Now

Linked**in**
✕ @OGConferences

DAY TWO

MORNING ROUNDTABLE DISCUSSIONS

08:30

Roundtable Discussion 1: Gene Therapies Utilising Stem Cells: Past, Present And Future
- Advent of cell-based therapies for cancer
- Current clinical trials and approved cell-based therapies for various cancer types
- Future Perspectives and non-cell-based approaches

Moderator: DEEPAK BHERE, Assistant Professor and Principal Investigator, **University of South Carolina**

Roundtable Discussion 2: How Will We Extend The Scope And Impact Of The Of Off-The-Shelf Immunomodulatory Therapy To Cold Tumours?

Moderator: RAHUL ROYCHOUDHURI, Professor, **University of Cambridge**

Roundtable Discussion 3: Improving Tumour Uptake, Penetration And Retention Of Biologics?
- Why have T cell engagers been relatively unsuccessful in solid tumour settings?
- What factors are involved in enhancing uptake, penetration and retention?
- Molecule size, affinity for targets, density of target expression, immunosuppressive tumour microenvironment, physical barriers.
- Are there combination therapies that could improve uptake?

Moderator: KENNETH CROOK, Head of Translational Medicine, **Engimmune Therapeutics**

TRACK 1: DISCOVERY & DEVELOPMENT: INTRATUMORAL/TARGETED IMMUNOTHERAPIES & ANTIBODY THERAPIES	TRACK 2: LARGE & SMALL MOLECULE-BASED PRECLINICAL & TRANSLATIONAL DEVELOPMENT & CANCER VACCINES	TRACK 3: INNOVATION & COLLABORATION TRACK
Track Chair: CHRIS LLOYD, Director, Protein Engineering & Novel Modalities, **AstraZeneca**	**Track Chair:** CAROL SZE KI LEUNG, Senior Immunologist, **Ludwig Institute, Oxford University**	**Track Chair:** RAJ MEHTA, Founder, Chief Executive Officer & Director, **Adendra Therapeutics**

09:00

Track 1:

Targeting The CD47-SIRPα Myeloid Checkpoint By BYON4228
- Discovery of the CD47-SIRPα checkpoint
- Considerations for CD47-SIRPα targeting
- Development of the anti-SIRPα antibody BYON4228

TIMO VAN DEN BERG, Senior Director, Immuno-Oncology, **Byondis**

Track 2:

Developing Potent Cancer Immunotherapies By Leveraging A Function-Based Target Discovery Platform
- iOTargTM is a versatile high-throughput target screening platform enabling the discovery of novel immuno-oncology targets
- IOMX-0675, a fully human antibody, identified from iOmx's proprietary phage display library antagonizes two immune-suppressive receptors, LILRB1 and LILRB2, expressed on myeloid and lymphoid cells
- Its highly differentiated binding profile and promising preclinical data support a best-in-class approach for IOMX-0675

CHRISTINE ROTHE, Chief Development Officer, **iOmx Therapeutics**

Track 3:

Presentation 1: Living Cures: Engineering A Synthetic Biology Platform For A New Class Of Immunotherapies
- Microbial immunotherapy acts locally by recruiting immune effectors and reducing suppression in the TME; and acts systemically by restoring immune fitness via long-term functional reprograming of myeloid cells
- Living Cures: A new class of programmable therapeutics

LIVIJA DEBAN, Chief Scientific Officer, **Prokarium**

Presentation 2: A First-In-Class Therapeutic Approach To Induce Tertiary Lymphoid Structures (TLS) In Solid Tumors To Generate Powerful Anti-Tumor Immune Responses
- Mestag is developing a first-in-class antibody-based therapeutic that conditionally induces TLS in solid tumors
- The presence of TLS is strongly correlated with survival and response to treatment and have recently been recognized as important drivers of anti-tumor immunity
- Acting as local lymph nodes, TLS are inducible immunological powerhouses that rapidly recruit, activate and educate anti-tumor immune cells

RAY JUPP, Chief Scientific Officer, **Mestag Therapeutics**

09:20

Track 1:

Solution Provider Presentation

Senior Representative, **GenScript Biotech**

Track 2:

Modelling The Tumour-Microenvironment Using Complex Immune: Tumour Cell Co-Cultures To Support Immuno-Oncology Drug Development

LAUREN SCHEWITZ-BOWERS, Senior Group Leader, **Charles River**

Track 3:

Delegates welcome to attend co-located sessions

09:40

Track 1:

CD25 Targeting With The Afucosylated Human IgG1 Antibody RG6292 Eliminates Regulatory T Cells And CD25+ Blasts In Acute Myeloid Leukemia
- Method: high-dimensional flow cytometry and RNA sequencing on samples from 37 AML patients and healthy donors, followed by ex vivo ADCC assays to evaluate the efficacy of CD25 Mab (RG6292/RO7296682) against regulatory T cells and CD25+ AML cells
- Results:
  » The study found a correlation between bone marrow and blood compositions in AML patients, with a higher prevalence of CD25+ AML cells in those with FLT3-ITD mutations or treated with hypomethylating agents and venetoclax. CD25 expression was highest on immature AML cell phenotypes
  » CD25 Mab demonstrated the potential to selectively kill CD25+ AML cells and regulatory T cells, suggesting that patients with these characteristics could benefit from this targeted therapy, which might reduce disease progression or relapse by depleting leukemic stem cells and progenitor-like AML cells

MARIA AMANN, Senior Principal Scientist, **Roche**

Track 2:

Therapeutic Cancer Vaccination With Viral Vectors Targeting Mage-Type Antigens In Lung Cancer
- The presentation will discuss the development of therapeutic cancer vaccines based on viral vectors and targeting tumor-specific shared antigens of the MAGE type, with a focus on the synergistic combination with chemotherapy and checkpoint inhibitors. Mechanistic aspects of this combination will be covered, and an ongoing clinical trial in lung and oesophageal cancer will be presented

BENOIT VAN DEN EYNDE, Professor, **Ludwig Institute for Cancer Research, Oxford University / VOLT**

Track 3:

Presentation 1: Cross Training Technology For Inducing Anti-Tumour Immunity
- Orthogonal approach to augmenting anti-tumour immunity by enhancing cross presentation of tumour derived antigens
- Neo-Antigen agnostic
- Multiple mechanisms of action

RAJ MEHTA, Founder, Chief Executive Officer & Director, **Adendra Therapeutics**

Presentation 2: PTT-4256: An Allosteric Orally Bioavailable Small Molecule Inhibitor Of The Ph Sensor Gpr65 For Cancer Immunotherapy
- Identification of GPR65 as a novel immuno-oncology target
- Validation of PTT-4256 as a potent GPR65 antagonist drug candidate

ALASTAIR CORBIN, Senior Scientist, **Pathios Therapeutics**

10:00

MORNING BREAK | 1-2-1 Meetings x4 | Poster Displays

Book Now

LinkedIn

@OGConferences

TRACK 1: DISCOVERY & DEVELOPMENT: INTRATUMORAL/ TARGETED IMMUNOTHERAPIES & ANTIBODY THERAPIES	TRACK 2: LARGE & SMALL MOLECULE-BASED PRECLINICAL & TRANSLATIONAL DEVELOPMENT & CANCER VACCINES	TRACK 3: INNOVATION & COLLABORATION TRACK

11:20

Functional Evaluation Of Immuno-Oncology Drug Candidates In Customized In Vitro Assays

CHRISTOPH SCHIFFLERS, Scientist Immuno-Oncology, **ImmunXperts, a Q2 Solutions Company**

ImmunXperts
a Q² Solutions Company

Preclinical Mouse Models For I/O Research

- Syngeneic models with dual genetic background
- Human Fc-dependent activity evaluation
- ADC in vivo and in vitro function with bystander effects

JIANMING XU, Director of In Vivo Pharmacology, **GemPharmatech**

GemPharmatech

Delegates welcome to attend co-located sessions

11:40

Panel Discussion: Modality Selection For Immunotherapies

- Different types of cancer immunotherapy
  » Checkpoint inhibitors
  » Chimeric
  » Engineered cell therapies
  » Targeted antibodies
  » Cytokines
  » Viruses
  » Bi- and trispecific antibodies
- Selection of modalities based on tumour type

Panellists:
CHRIS HOLLAND, Senior Manager, Research, Experimental Immunology, **Immunocore**
MIGUEL GASPAR, Director, **AstraZeneca**
AMIT GROVER, Associate Principal Scientist, **AstraZeneca**

Panel Discussion: Cancer Vaccines As Immuno Therapeutics

- Mechanisms of cancer vaccines
- Platforms
- Current progress in:
  » Cell-based cancer vaccines
  » Virus-based cancer vaccines
  » Peptide-based cancer vaccines
  » mRNA-based cancer vaccines

Moderator: JONATHAN KWOK, Chief Executive Officer, **Infinitopes**

Panellists:
BENOIT VAN DEN EYNDE, Professor, **Ludwig Institute for Cancer Research, Oxford University / VOLT**
JON MOORE, Chief Scientific Officer and Co-Founder, **Epitopea**

Using An Innovative Personalised Human Tumour Slice Model For Real-Time Immune System Monitoring

- This talk covers pre-clinical models of human cancer for immunotherapy testing and personalisation
- I will discuss the development of an in vitro model platform for investigation of the replete immune microenvironment of human cancers
- The talk will outline how we are able to derive predictive information from patient material that can inform treatment responses to standard of care, novel regimens and cell based therapy
- I will also highlight novel discoveries of tissue resident NK cells in pancreatic cancer and how this may have wider implications

ERIC O'NEILL, Professor of Cell and Molecular Biology, **University of Oxford**

Workshop: Advances In Oncolytic Virotherapies: Exploring The Latest Developments And Real-World Use Cases
Presentation 1 (10min): Novel Platforms For Oncolytic Virus-Based Cancer Immunotherapy

- PeptiCRAd is a novel cancer immunotherapy platform with multifaceted mode-of-action. PeptiCRAd modulates tumor microenvironment, attracts TILs and can be tailored to trigger systemic cytotoxic T-cell responses against multiple tumor antigens simultaneously. Phase 1 clinical testing with lead candidate PeptiCRAd-1 in combination with pembrolizumab is ongoing in multiple solid tumor indications

SARI PESONEN, Chief Scientific Officer, **Valo Therapeutics**

Presentation 2 (10min): VET3-TGI, A Systemically Deliverable Oncolytic Virus Targeting TGF-Beta

- Combining enhanced systemic virus delivery to CXCR3 ligand rich tumours and locally expressed IL-12 and TGFBi within the tumour microenvironment

STEPHEN THORNE, Chief Scientific Officer, **KaliVir Immunotherapeutics**

Presentation 3 (10min): Oncolytic Molecules Address The Major Challenge In Current Cancer Therapy

- Solid tumors consist of a number of different cancer cell with different unique mutations, making it very difficult to cure cancer
- Our oncolytic molecules have a potential to overcomes this major challenge by generating broad tumor-specific immune responses via their unique dual mode of action

ØYSTEIN REKDAL, Chief Executive Officer, **Lytix Biopharma**

12:00 *(timing column marker)*

12:20

Preclinical Characterization of ISB 2001, a BCMAxCD38xCD3 T-Cell Engager For Relapsed/Refractory Multiple Myeloma

- ISB 2001 is a first-in-class T cell-engaging trispecific antibody currently in Phase 1 clinical trial
- In vitro and in vivo studies showed that ISB 2001 exhibit superior killing potency compared to single-targeting clinical benchmarks
- ISB 2001 is designed to overcome escape mechanisms of multiple myeloma tumor cells

MARIA PIHLGREN BOSCH, Senior Director and Project Team Leader, **IGI**

Panel Discussion: Evaluating The Future Of Solid Tumour Immunotherapies

- Latest successes of current immunotherapies
- Solid tumour microenvironment
- Emerging technologies, e.g. CRISPR-CaS 9
- Combinations with radio- and chemotherapy

Moderator: JOHN MAHER, Chief Scientific Officer, **Leucid Bio**
Panellists:
LIVIJA DEBAN, Chief Scientific Officer, **Prokarium**
PEDRO CORREA DE SAMPAIO, Chief Executive Officer, **Neobe**

Presentation 1: The Influence Of Small Molecules On The Immune System And Their Role As Anti-Cancer Medications

- Targeted small molecules have significantly improved outcomes for a number of cancer types
- The impact of such therapies on the anti-cancer immune response is often poorly understood
- A better understanding of how therapeutics impact the anti-tumour immune response will aid the design of biologically rational combination therapies

PHILIP BEER, Chief Scientific Officer, **Step Pharma**

Presentation 2: Cancer Immunotherapies Targeting Glycobiology

- Sialoglycans on tumor and immune cell surfaces cause immune evasion in many cancers by interacting with multiple immune receptors. Based on over a decade of research, GlycoTherapeutics developed small molecules which inhibit sialoglycan expression in mice, human organoids and cell line models

JOHAN PIJNENBORG, Chief Executive Officer, **GlycoTherapeutics B.V.**

12:40

LUNCH BREAK | 🤝 1-2-1 Meetings x3 | 🖼 Poster Displays

Book Now

Linked**in**
✕ @OGConferences

	TRACK 1: DISCOVERY & DEVELOPMENT: INTRATUMORAL/ TARGETED IMMUNOTHERAPIES & ANTIBODY THERAPIES	TRACK 2: LARGE & SMALL MOLECULE-BASED PRECLINICAL & TRANSLATIONAL DEVELOPMENT & CANCER VACCINES	TRACK 3: INNOVATION & COLLABORATION TRACK
	Track Chair: CHRIS LLOYD, Director, Protein Engineering & Novel Modalities, **AstraZeneca**	**Track Chair:** ELENI CHANTZOURA, Director of Discovery, **MiNK Therapeutics**	**Track Chair:** JOHN MAHER, Chief Scientific Officer, **Leucid Bio**
13:40	**Expanding The ImmTAX Platform To Gamma Delta T Cell Targets** • Introduction to the Immunocore ImmTAX Platform and the first approved TCR bi-specific therapeutic. • Establishment of a γδ TCR discovery platform • Development of an affinity enhanced γδ TCR CHRIS HOLLAND, Senior Manager, Research, Experimental Immunology, **Immunocore**	**Workshop: Small Molecule-Based Immunotherapies - Presentation 1:** Small Molecule Combination Approaches To Enhance Immunotherapy Response • While immune checkpoint inhibitors can give durable benefit, combination treatments targeting tumour cells or resistance mechanism in the TME can enhance or re-invigorate therapeutic response. Small molecule combination approaches targeting different aspects of tumour biology to enhance the anti-tumour immune response will be discussed SIMON BARRY, Executive Director, **AstraZeneca**	**Presentation 1: The Development Of Antagonist Monoclonal Antibodies To The TNF Superfamily** • Multiple cell types in the tumor microenvironment (TME) express TNFR2 and contribute to immunosuppression and resistance to checkpoint inhibitors and CART. A novel antagonistic antibody to TNFR2 depletes TME suppressive cells and increases CD8 effector T lymphocytes resulting in tumor cell death in multiple models RUSSELL LAMONTAGNE, Chief Executive Officer, **Boston Immune Technologies and Therapeutics, Inc.** **Presentation 2: Configuring Novel Shared Tumour-Specific Antigens (Tsas) To Build The Best Cancer Vaccines In The World** • Mass-spec led analysis of the class I immunopeptidome encoded by cancer specific transcripts reveals most TSA are encoded by junk DNA, not canonical mutation bearing exons • Such cryptic TSAs are far more shared than mutation-bearing neoantigens that mostly derive from non-recurrent passenger mutations • Enables therapeutic vaccines blending tumour specificity of personalised vaccines with off the shelf translatability of traditional TAAs JON MOORE, Chief Scientific Officer and Co-Founder, **Epitopea**
14:00	**ATOR-4066 – A Neo-X-Prime™ Bispecific Antibody Engaging Myeloid Cells For Immunotherapy Of CEACAM5-Expressing Cancers** • Neo-X-Prime bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in a superior anti-tumor response compared to monospecific antibodies • ATOR-4066, the lead Neo-X-Prime candidate drug targeting CD40 and CEACAM5, has been engineered to have fine-tuned target affinity and optimal functional and safety properties IDA UDDBÄCK, Senior Scientist, **Alligator Bioscience**	**Presentation 2:** The Role Of Phosphoinositide 3-kinase (PI3K) Inhibitors In Immunotherapy • We have previously shown that inhibiting PI3Kδ in Treg unleashes a potent immune response against cancers. Paradoxically, immune-checkpoint inhibitors act in part by increasing PI3K activity in effector T cells. Moreover, we and others have shown that intermittent dosing of PI3K inhibitors can be at least as effective, and potentially safer, than continuous dosing • I will present data on anti-tumour immune responses and how these are affected by various degrees of PI3Kδ inhibition or activation in selected T cell subsets. Further, I will present data suggesting differential immune regulatory processes controlling primary and metastatic cancers KLAUS OKKENHAUG, Professor of Immunology, **University of Cambridge**	**Presentation 1: PLT012, A Monoclonal Antibody Targeting CD36, Unleashes Anti-Tumour Immunity Via Metabolic Reprogramming In Tumour Microenvironment** • PLT012 possesses an innovative dual MOA, which blocks CD36-mediated fatty acid uptake simultaneously in intratumoral Treg and CD8+ TILs with remarkable anti-tumor efficacy in HCC. This superior anti-tumor action results in reprogramming of the tumor microenvironment toward an immunosupportive one, which further enhances the therapeutic effects of current ICB therapies YI-RU YU, Senior Scientist, **Pilatus Biosciences** **Presentation 2: CAR T-Cell Immunotherapy Of Solid Tumours: Moving Through The Generations** • Summary of a phase 1 clinical trial of a panErbB CAR followed by a discussion of Leucid's lateral CAR platforms JOHN MAHER, Chief Scientific Officer, **Leucid Bio**
14:20	**Next-Generation Of DARPin-based Therapeutics For Immunotherapy** • Introduction to DARPins as a novel therapeutic modality • Conditionally activated DARPin therapeutics for Immuno-Oncology: • MP0533: Multi-specific DARPin for AML • Switch DARPin: Next generation of Immune Cell Activators NATALIA VENETZ, Senior Scientist, Oncology Research, **Molecular Partners**	**Panel Discussion:** Small Molecule Drug Development Strategies In Immuno-Oncology • The balance between toxicity and clinical efficacy in cancer immunology **Moderator**: SIMON BARRY, Executive Director, **AstraZeneca** **Panellists**: KLAUS OKKENHAUG, Professor of Immunology, **University of Cambridge** PHILIP BEER, Chief Scientific Officer, **Step Pharma**	**Presentation 1: Off-The-Shelf Precision Vaccines To Deliver Affordable Cancer Therapies** • Oncology, immunology, antigen discovery, vaccinology & biomanufacturing • Preclinical results • mRNA technology JONATHAN KWOK, Chief Executive Officer, **Infinitopes** **Presentation 2: Targeted Delivery Of Neoantigens To Apcs Using The Adaptable Drug Affinity Conjugate (ADAC) Technology** • Overview of the ADAC technology and STRIKE2011 • Improving T-cell expansion/activation using ADAC • Flexibility of ADACs affinity-based technology in a personalized setting PIERRE DÖNNES, Co-Founder, **Strike Pharma AB**

Book Now

TRACK 2: INNOVATION & COLLABORATION SESSIONS	TRACK 3: INNOVATION & COLLABORATION TRACK

14:40

TRACK 2:

Presentation 1: Allogeneic iNKT Cell Therapies For Oncology And Other Immune Mediated Diseases
- MiNK's invariant Natural Killer T (iNKT) cells as an allogeneic cell therapy platform to address unmet needs in the treatment of immune-regulated diseases
- MiNK's in-house scalable manufacturing capabilities can produce thousands of iNKT doses from a single healthy donor providing quick access to patients all over the world while increasing robustness and reproducibility of the treatment
- MiNK has developed a variety of discovery approaches to enhance and tune iNKT functionality while maintaining safety

ELENI CHANTZOURA, Director of Discovery, **MiNK Therapeutics**

Presentation 2: Creating A Urine Cell And Protein Immune Profiling Strategy To Monitor Local Changes In Non-Muscle Invasive Bladder Cancer
- Examining urinary biomarkers plays a vital role in comprehending immune responses and therapeutic effectiveness in NMIBC and other urological conditions. Certain challenges emerge from the constrained urine cellularity, the requirement for biomarker normalization, and uncertainties surrounding the stability of biospecimens during transit and laboratory procedures. This study aims to assess urine leukocyte and protein stability and to explore the feasibility of their analysis while accounting for normalization factors

ALEXANDRA SEVKO, Director, Translational Research, **Prokarium**

TRACK 3:

Presentation 1: Developing High Affinity And Soluble Multi-Specific TCRs For Cancer Therapy
- Using protein engineering and AI alongside our other platforms we are developing affinity matured TCRs with high specificity, a clean safety profile, and enhanced manufacturability. These can be coupled to selected immunoligands to optimise anti-tumour efficacy

KENNETH CROOK, Head of Translational Medicine, **Engimmune Therapeutics**

Presentation 2: Unlocking Hidden Potential In Cancer Therapy: Targeted Disruption Of GDF-15-Mediated Immunoresistance As A New Backbone To Current Standard Of Care Therapies
- Examining GDF-15's role in cancer therapy resistance, this talk presents insights from visugromab (CTL-002), a first-in-class GDF-15-neutralizing antibody in Phase 2 trials (NCT04725474), and shows how GDF-15 blockade can boost current SOC cancer therapies and improve patient outcomes

THORSTEN ROSS, Vice President, Preclinical Research & Translation Strategy, **CatalYm**

15:00

Presentation 1: Arenavirus-Based Immuno-Virotherapy: Efficacious Anti-Tumor Activity Combined With Advantageous Effects On The Tumor Microenvironment (TME)
- Engineering a non-oncolytic immuno-virotherapy based on the Lymphocytic Choriomeningitis Virus with enhanced tumor cell targeting
- AdaptInnate platform: utilizing arenavirus-based immuno-virotherapy for efficacious anti-tumor activity combined with strong and advantageous remodeling of the tumormicroenvironment

SARAH-KIM FRIEDRICH-BECKER, Senior Principal Scientist, **Abalos Therapeutics**

Presentation 1: Preclinical/Clinical Development Of A Neo-Epitope Targeted Monoclonal Antibody For Cancer Therapy
- Screening and identification of tumor specific monoclonal antibodies
- Functional testing and target identification of NEO-201 mab
- Mechanisms of action for NEO-201
- Clinical data and future plans

PHILIP ARLEN, Chief Executive Officer, **Precision Biologics**

Presentation 2: Tumor-Specific Immuno-Gene (T-SIGn®) Therapeutics Drive Selective Intratumoral Expression Of Immunotherapeutic Molecules Following Intravenous Delivery
- Overview of the T-SIGn® platform and Akamis bio's pipeline
- T-SIGn® vectors expressing T cell-activating cytokines, chemokines, and CAR-T cell target antigens preclinically synergize with T Cell Therapy for enhanced therapy potency and specificity
- T-SIGn® platform potential for versatile tumor-specific expression of immune agonist antibodies, checkpoint inhibitors and bispecific T cell engagers

MARIA STELLA SASSO, Senior Principal Scientist, **Akamis Bio Ltd**

15:20 — **End of Congress**

Book Now

Linked in

𝕏 @OGConferences

Be Part of Something Exceptional

Novotel London West

1 Shortlands, Hammersmith International
Ctre, Hammersmith, W6 8DR, London, UK

Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK. This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.

By Air
London Heathrow Airport - Novotel London West is accessible from Heathrow via the Underground on the Piccadilly Line - fares cost around £5 into Central London. A taxi from the airport will take approximately 20 minutes and will cost around £30 - £40.

London Gatwick Airport - The Gatwick Express runs every 15 mins - take it to Victoria station, and then get the District line to Hammersmith (about 15 mins). A taxi from the airport will take around 60 mins and cost between £65 - £80.

By Underground & Bus
Hammersmith Underground Station is adjacent to the hotel (3 minutes walk) with access to the Piccadilly, District and Hammersmith & City Lines. When exiting Hammersmith station, turn right and walk across the bus station. Cross over the roads using the island and keep on the right-hand side of Hammersmith Road. Continuing walking for 2 mins, and the hotel is accessible via stone steps.

For buses in central London, take route numbers 9 and 10. The main coach station (London Hammersmith) is 3 minutes walk away.

By Rail
The closest National Rail train station is Kensington Olympia (20 minutes walk).

By Car
Leave the A4 at the Hammersmith turning and proceed along Hammersmith Bridge Road to the large roundabout underneath the flyover. Take the fifth exit off the roundabout. Then turn left into Shortlands - the main hotel entrance and parking will be on your left-hand side.

Parking
Novotel London West offers over 240 on-site car parking spaces (charged per hour for residents parking). For further information including a map and full directions, please visit: www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml

Please **click here to visit the hotel's website** & to recieve more information on Novotel London West

Book Now

Linked in

X @OGConferences

IMMUNO 2024
NETWORKING DRINKS

Thursday 25th April, 17:10
in the Exhibition Hall

We hope to see you there

OXFORD GLOBAL CONFERENCES

Book Now

Linked in

X @OGConferences

Oxford Global PLUS Pass

Your Gateway to a Year of Unparalleled Knowledge-Sharing, Curated Experiences, and Global Networking!

OXFORD GLOBAL PLUS

Welcome to the future of life sciences engagement!

Effortless On-Demand Presentations

Immerse yourself in competitor case studies, groundbreaking market developments, and captivating high-level strategy discussions via our comprehensive library of on-demand presentations.

Beneficial Partnerships and Accelerated Learning

Foster invaluable partnerships for your business and accelerate high-end learning through peer-to-peer interactions. Participate in regular science exchange sessions, engaging group discussions, and dynamic in-person and online events that drive professional growth.

Year-Round Exclusive Insights

Unlock a world of exclusive insights throughout the year via our online platform. Enjoy unrestricted access to commentaries, interviews with Key Opinion Leaders (KOLs), industry reports, and curated market intelligence content, keeping you at the forefront of industry trends.

Featuring content & recordings from all Oxford Global brands:

- BIOLOGICS BY OXFORD GLOBAL
- BIOMARKERS BY OXFORD GLOBAL
- CELL & GENE BY OXFORD GLOBAL
- DISCOVERY BY OXFORD GLOBAL
- FORMULATION & DELIVERY BY OXFORD GLOBAL
- IMMUNO BY OXFORD GLOBAL
- OMICS BY OXFORD GLOBAL

Digital Pass
£459 +VAT
$700 +VAT

Register Now

To receive bespoke proposal for group packages contact us at **pluspass@oxfordglobal.com**

*Please note: PLUS Passes are unavailable to service and solution providers/vendor companies

Book Now

Linkedin
X @OGConferences

IMMUNO SERIES ACROSS 2024

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations.

Immuno 2024

25 - 26 April 2024 | London, UK

Microbiome Drug Development: Online Symposium

24 September 2024 | BST (UTC+1)

Biomarkers & Immuno US 2024

28 - 29 October 2024 | San Diego, USA

Biologics Series

Proteins & Antibodies | Peptides| Oligonucleotides
Sustainability in Biologics | ADC Discovery & Development
Vaccines | Oligonucleotides Chemistry & Therapeutics

Biomarkers Series

Biomarkers | Biomarker & Precision Medicine
Precision Oncology

Cell & Gene Series

Gene Therapy Development
Cell Culture Advanced Therapy Development
Cell & Gene Therapy Manufacturing

Discovery Series

Organ Modelling | 3D Cell Culture
Drug Discovery Summit & Discovery Chemistry
Neuroscience Drug Development
SmartLabs Automation & Robotics

Formulation & Delivery Series

Formulation & Drug Delivery
Inhalation & Respiratory Drug Delivery
RNA Therapeutics & Delivery

Omics Series

Next Generation Sequencing
Single Cell & Spatial Analysis | Synthetic Biology
Next Generation Sequencing & Clinical Diagnostics
Digital PCR & Liquid Biopsies |
Synthetic Biology in Discovery & Therapeutics
Spatial Biology

Visit **www.oxfordglobal.com/calendar/** to explore our diverse portfolio of events across 2024.

Book Now

12-MONTH CONTENT AND COMMUNITY ACCESS
Oxford Global PLUS Pass

Oxford Global PLUS Pass includes unrestricted access to all events shown above and much more

Register Now

To receive bespoke proposal for group packages contact us at pluspass@oxfordglobal.com

Linked in
X @OGConferences

OXFORD GLOBAL PLUS